September 18, 2020
On September 16, 2020, the Feds issued an Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 that allows for the Minister of Health to expedite review of COVID-19 drugs in Canada. There are three routes.
August 21, 2020
Sometimes the new normal is simply dealing with a new level of systematic complexity that arises as the health economy and population grows, and we grapple with an ever-expanding landscape of health system needs that are as complex as they are diverse.
July 9, 2020
On July 8, the PMPRB updated its website to include its views on the recent Federal Court decision pertaining to the amendments to the Patented Medicines Regulations and their impact on the Guidelines.
June 22, 2020
Join our team: Pangaea is seeking a part-time / independent consultant to support our trade team as a Trade Manager.
June 3, 2020
Overall, there are 14 projects under the R2D2 initiative that can be bucketed into four categories. Read more.
June 2, 2020
It will be critical for companies to be aware of external policies to find the right balance of criteria for re-entry into clinics & hospitals to ensure a safe and productive interaction for the benefit of Canadian patients.
May 29, 2020
Pangaea confirms the amendments to the Patented Medicines Regulations to take effect July 1, 2020, will be implemented January 1, 2021.
April 3, 2020
As the home office environment is new to many in this industry, we thought we would share some best practices for working virtually.
April 2, 2020
The PMPRB plans to publish revised draft Guidelines this spring, that will have only a limited time-frame for feedback before being finalized.
March 26, 2020
On March 25, Bill C-13, the COVID-19 Emergency Response Act, received Royal Assent that includes amendments to both the Patent Act and the Food and Drugs Act to ensure the availability of drugs and medical devices.